GeneDx Holdings (GeneDx Holdings) Cash-to-Debt : 1.09 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is GeneDx Holdings Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. GeneDx Holdings's cash to debt ratio for the quarter that ended in Dec. 2023 was 1.09.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, GeneDx Holdings could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for GeneDx Holdings's Cash-to-Debt or its related term are showing as below:

WGS' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.09 Med: 2 Max: 27.78
Current: 1.09

During the past 5 years, GeneDx Holdings's highest Cash to Debt Ratio was 27.78. The lowest was 1.09. And the median was 2.00.

WGS's Cash-to-Debt is ranked better than
58.02% of 655 companies
in the Healthcare Providers & Services industry
Industry Median: 0.74 vs WGS: 1.09

GeneDx Holdings Cash-to-Debt Historical Data

The historical data trend for GeneDx Holdings's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

GeneDx Holdings Cash-to-Debt Chart

GeneDx Holdings Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

N/A

2.40

27.78

1.61

1.09

GeneDx Holdings Quarterly Data
	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial										1.61	2.68	2.08	1.55	1.09

Competitive Comparison of GeneDx Holdings's Cash-to-Debt

For the Health Information Services subindustry, GeneDx Holdings's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GeneDx Holdings's Cash-to-Debt Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, GeneDx Holdings's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where GeneDx Holdings's Cash-to-Debt falls into.

GeneDx Holdings Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

GeneDx Holdings's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	130.148	/	(4.144	+	115.626)
	=	1.09

GeneDx Holdings's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	130.148	/	(4.144	+	115.626)
	=	1.09

GeneDx Holdings (NAS:WGS) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

GeneDx Holdings Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of GeneDx Holdings's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

GeneDx Holdings (GeneDx Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » GeneDx Holdings Corp (NAS:WGS) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

333 Ludlow Street, North Tower, 6th Floor, Stamford, CT, USA, 06902

Website

https://www.genedx.com

GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets. It has two segments GeneDx and Legacy Sema4 diagnostics.

Executives

Kareem Saad	officer: Chief Business Officer	C/O SEMA4 HOLDINGS CORP, 333 LUDLOW STREET, NORTH TOWER, 8TH FL., STAMFORD CT 06902
Katherine Stueland	director, officer: Chief Executive Officer	458 BRANNAN STREET, SAN FRANCISCO CA 94107
Kevin Feeley	officer: Chief Financial Officer	C/O SEMA4 HOLDINGS CORP, 333 LUDLOW STREET, NORTH TOWER, 8TH FL., STAMFORD CT 06902
Jason Ryan	director	C/O FOUNDATION MEDICINE, INC., ONE KENDALL SQUARE, SUITE B3501, CAMBRIDGE MA 02139
Keith A. Meister	director, 10 percent owner	C/O ICAHN CAPITAL LP, 767 FIFTH AVENUE, SUITE 4700, NEW YORK NY 10153
Pfenniger Richard C Jr	director	4400 BISCAYNE BLVD., MIAMI FL 33137
Karen Ann White	officer: Chief People Officer	C/O SEMA4 HOLDINGS CORP, 333 LUDLOW STREET, NORTH TOWER, 8TH FL., STAMFORD CT 06902
Casdin Partners Fo1-msv, Lp	director, 10 percent owner	C/O CASDIN PARTNERS GP, LLC, 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019
Casdin Partners Master Fund, L.p.	director, 10 percent owner	WALKER HOUSE, 87 MARY STREET, GEORGE TOWN E9 KY1-9001
Eli Casdin	director, 10 percent owner	1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Casdin Capital, Llc	director, 10 percent owner	1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019
Casdin Partners Gp, Llc	director, 10 percent owner	1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Icahn School Of Medicine At Mount Sinai	10 percent owner	1 GUSTAVE L. LEVY PLACE, NEW YORK NY 10029
Corvex Management Lp	director, 10 percent owner	667 MADISON AVENUE, NEW YORK NY 10065
Opko Health, Inc.	10 percent owner	4400 BISCAYNE BLVD., MIAMI FL 33137